JP5998139B2 - 1,5−ジフェニル−ペンタ−1,4−ジエン−3−オン化合物 - Google Patents
1,5−ジフェニル−ペンタ−1,4−ジエン−3−オン化合物 Download PDFInfo
- Publication number
- JP5998139B2 JP5998139B2 JP2013525975A JP2013525975A JP5998139B2 JP 5998139 B2 JP5998139 B2 JP 5998139B2 JP 2013525975 A JP2013525975 A JP 2013525975A JP 2013525975 A JP2013525975 A JP 2013525975A JP 5998139 B2 JP5998139 B2 JP 5998139B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- alkyl
- cancer
- compounds
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
- C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
- C07C217/22—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by carbon atoms having at least two bonds to oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
- C07C49/24—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups
- C07C49/245—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups containing six-membered aromatic rings
- C07C49/248—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups containing six-membered aromatic rings having unsaturation outside the aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/121—Ketones acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
- C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/82—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C307/02—Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
- C07C309/66—Methanesulfonates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/67—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/24—Sulfones; Sulfoxides having sulfone or sulfoxide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
- C07C49/227—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing halogen
- C07C49/233—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
- C07C49/235—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings having unsaturation outside the aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
- C07C49/255—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/12—Acetic acid esters
- C07C69/16—Acetic acid esters of dihydroxylic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/68—One oxygen atom attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids R2P(=O)(OH); Thiophosphinic acids, i.e. R2P(=X)(XH) (X = S, Se)
- C07F9/32—Esters thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids R2P(=O)(OH); Thiophosphinic acids, i.e. R2P(=X)(XH) (X = S, Se)
- C07F9/32—Esters thereof
- C07F9/3258—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
- C07F9/3282—Esters with hydroxyaryl compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Description
本出願は、2010年8月20日に提出された米国仮出願番号第61/375、534号に対して優先権を主張する。当該出願に含まれるものは、全体として参照により本明細書中に組み込まれる。
シグナル伝達兼転写活性化因子(Signal Transducer and Activator of Transcription:STAT)タンパク質は、成長因子に対する細胞応答を仲介する転写因子である。これらのタンパク質は、成長因子受容体型チロシンキナーゼによるチロシンリン酸化を介して活性化される。活性化されたSTATタンパク質は、細胞生存および増殖を促進する。STAT3またはSTAT5が恒常的に活性化されることによって、細胞増殖、浸潤、および固形癌および造血器癌の転移が促進されることは、広く認識されている。たとえば、Expert Opin. Investig. Drugs, 2009, 18(1): 45-56を参照されたい。
本発明は、1,5−ジフェニル−ペンタ−1,4−ジエン−3−オン骨格を有する化合物群が、STATタンパク質を不活性化するという発見に基づいている。
XはそれぞれNまたはCHであり;R1、R2、R3、R4、R5、R1’、R2’、R3’、R4’、およびR5’は、それぞれ独立して、H、アルキル(たとえば、ハロゲンまたはSO2Rdで置換されたアルキルである)、ハロゲン、OH、Rc−O−、RdS(O)2−O−、または(Rd)2P(O)−O−であり、Rcは無置換のアルキル、若しくはハロゲン、OH、アルコキシ、アミノ、シクロアルキル、ヘテロシクロアルキル、アリール、若しくはヘテロアリールで置換されたアルキルであり、かつ、Rdは、H、OH、アルキル、アルコキシ、アミノ、またはアリールであり;かつ、
R6はC(O)−Re、C(O)NReRf、またはアルキルであり(たとえば、無置換のアルキルまたはシクロアルキルで置換されたアルキルである);ReおよびRfは、それぞれ独立して、アルキルまたはシクロアルキルである。
上記化合物は、技術的に公知の方法によって調製される。以下のスキーム1、2、および3に、式(I)、(II)、および(III)の化合物をそれぞれ合成するために用いられる一般的な合成経路を示す。
以下の具体例は単に例示のためのものであって、開示の残部をいかようにも制限するものではない。さらに実験することなく、当業者であれば、本明細書の記載に基づいて本発明をその全体にわたって実施可能であると考えられる。本明細書で引用されている全ての文献は、その全体が参照により本明細書に引用される。
本明細書中で用いられる場合の融点は、フィッシャー−ジョン(Fisher−John)融点装置によって決定され、校正されていないものである。プロトン核磁気共鳴(1H NMR)および13C NMRスペクトルについては、テトラメチルシラン(TMS)を内部標準として、ヴァリアン ジェミニ(Varian Gemini)300またはイノヴァ(Inova)400スペクトロメーターによって測定した。化学シフトはδ(ppm)として報告された。質量スペクトル(MS)については、島津LCMS−2010によって得た。コンビフラッシュクロマトグラフィシステムについては、一般的な分離・精製用のグレース(Grace)シリカゲルカートリッジを用いて行った。シリカゲルプレート(キーセルゲル(Kieselgel) 60, F254, 1.00 mm)を用いた分取薄層クロマトグラフィもまた、分離および精製のために用いた。予め被覆されたシリカゲルプレート(キーセルゲル(Kieselgel)60, F254、0.25mm)を、薄層クロマトグラフィ(TLC)分析に用いた。すべての試薬および溶媒は、アルドリッチ(Aldrich)、フィッシャー(Fisher)、VWR、または他の業者から購入した。
化合物1〜4および21を、以下のスキーム4に示すように調製した:
化合物20、30、31、38、39、41、42、44、62〜64、73、および75を、以下のスキーム5に示すように調製した:
化合物12、13および15〜17を、Roberta Costiらによる、Bioorganic & Medicinal Chemistry 2004, 12: 199-215に開示された方法を基に、これを修正した方法により、以下のスキーム6に示すように調製した。
これら化合物の合成を、スキーム7に示す。
ヒト レンネルト(Lernert’s)T細胞リンパ腫KT−3の増殖に対する抑制効果
Lennert’s T細胞リンパ腫KT−3細胞、IL−6−依存性細胞株の成長に対する本発明の化合物の抑制効果を、以下のように測定した。簡単に言えば、KT−3細胞を96−ウェルプレートのウェル内に移入し(2.5×103/ウェル)、ペニシリン(25U/ml)、ストレプトマイシン(25μg/ml)、10%非働化ウシ胎児血清(FBS)、およびhIL−6(2.5ng/ml、R&Dシステムズ)を含むRPMI−1640培地(GIBCO)内で培養した。細胞を配置した後、試験用のセルに、様々な濃度(3種類)の試験化合物を速やかに加えた。コントロールのウェルには、同体積の賦形剤、DMSO(0.1%v/v)を加えた。化合物が添加された細胞または賦形剤中の細胞を48時間培養した後、CellTiter Glo Luminescent Cell Viability アッセイキット(プロメガ、マディソン、WI)を用いて、細胞の生存を評価した。結果として生じる発光を、製造元のプロトコールに従ってMicroplate Luminometer LB96V (EG&Gベルトールド)を用いて定量化した。化合物処理された細胞の発光値を賦形剤処理された細胞の発光値で割ることにより、細胞生存率を算出した。
以下の記載のように、大腸癌細胞(HCT116,HT29,SW480,およびSW620)、結腸線癌細胞(Colo205)、前立腺腺癌細胞(PC-3およびDul45)、前立腺癌細胞(CWR22RVおよびLNCap)、非小細胞肺癌細胞(NCI-H1299)、肺腺癌細胞(A549)、大細胞肺癌細胞(NCI-H460)、転移性乳癌細胞(MDA-MB-453)、乳管癌細胞(T-47D)、乳腺癌細胞(MCF7)、肝細胞癌細胞(Huh-7およびHepG2)、膵臓癌細胞(PANC-1)、子宮頚部腺癌細胞(Hela)、IL−6−依存性Lennert’s T細胞リンパ腫細胞(KT-3)、IL-6-依存性多発性骨髄腫細胞(INA-6)、多発性骨髄腫細胞(KMM-1およびU266)、骨髄性白血病細胞(HL-60)、およびT細胞白血病細胞(Jurkat)の成長に対する、化合物6の抑制効果を評価した。簡潔に言えば、癌細胞を1×103〜4×103/ウェルまでの範囲の密度で96−ウェル マイクロテストIII組織培養プレート(ファルコン、NJ)内に播種した。ペニシリン(25ユニット/ミリリットル)、ストレプトマイシン(25マイクログラム/ミリリットル)、および10%非働化FBSを含むDMEM(GIBCO)中で12時間培養した後、細胞を、0から5μMに及ぶさまざまな濃度の化合物6で72時間処理した。その後、腫瘍細胞の生存能力をテトラゾリウム熱量測定アッセイ(MTT)を用いて、Suらによる、J Mol Cell Cardiol. 1998; 30:587-598に記載されたように評価した。細胞をMTT色素(5mg/mL)とともに37℃で3時間培養した。得られるホルマザン結晶を、MTT溶解バッファー(50%DMF、24mM HCl、2%酢酸、5%SDS)で可溶化し、595nmにおける吸収を、Benchmarkマイクロプレートリーダー(バイオ−ラッド、ヘラクレス、CA)を用いて測定した。化合物処理された細胞の吸収値対賦形剤処理された細胞の吸収値により、細胞生存率を算出した。
Kawashimaらによる、J. Immunol. 2001, 167:3652-3660に記載された方法にわずかな変更を加えてウェスタンブロット分析を行った。簡潔に言えば、上記のIL−6−含有培地内において、KT−3細胞を1、5、若しくは20μMの化合物6または賦形剤単独で処理した。培養後、さまざまな時点で(すなわち、処理後0.5、1、3、および6時間)、細胞を採取し、氷上で30分間、2×107セル/mlで溶解バッファー(1.0%トリトンX−100、50mMトリス−HCl(pH7.5)、0.1mM EDTA、150mM NaCl、200μM Na3VO4、50mM NaF、1mM ジチオトレイトール、0.4mM フェニルメチルスルホニルフルオリド、3μg/mlのアプロチニン、2μg/mlのペプスタチンA、1μg/mlのロイペプチン)を用いて溶解させた。12,000xgで15分間遠心分離することにより細胞の溶解物を採取した。サンプル(1×105細胞当量/レーン(cell equivalent/lane))をドデシル硫酸ナトリウムポリアクリルアミドゲル電気泳動し、その後、Immobilonフィルター(ミリポア)上へ転写した。5%BSAでブロックキングした後、フィルターについて、anti-pSTAT3、STAT3、STAT5、STAT1、MRGまたはActin抗体をプローブとした。ウサギポリクローナルanti-STAT3、anti-STAT5、anti-STAT1、およびanti-Actin抗体(Abs)、ならびにマウスモノクローナルanti-pSTAT3抗体(B-7)をサンタクルーズバイオテクノロジーから調達した。アフィニティー精製した(Affinity purified)anti-MRG抗体を、以前にHiroseらにより、J. Biol. Chem. 276:5821-5828に記載されたように調製した。フィルターをさらにHRP標識二次抗体とともに培養した。最終的に、タンパク質を増強化学発光(Enhanced Chemiluminescence, ECL)システム(アマシャム)を用いて可視化した。
動物管理使用委員会承認のプロトコールの下で、研究における人間による動物の使用についての委員会指針に従って、イン・ビボ(in vivo)実験を行った。6週齢の雌の無胸腺ヌードマウスをハーレンラボラトリー(Harlan Laboratory)から購入した。8匹のマウスのそれぞれに、マトリゲル(Matrigel,BDバイオサイエンス)を混合した1×106個のHCT−116細胞を左脇腹に皮下注射した。注射した後、処置する前に腫瘍を5日間成長させ、触知できる大きさ(体積〜100mm3)とした。マウスをランダムに2つの群に分けた(1群当たりn=4)。コントロール群には、賦形剤溶液のみ(すなわち、10%DMSOおよび90%コーンオイル)を注射し、一方、実験群には化合物6(1回の投与量40mg/kg体重、賦形剤溶液中に溶解させた)を、0日目(注射を行った日)から4日目および7〜10日目に毎日注射した(i.p.)。ノギスを用い、以下の式(式:長さ×幅×高さ×0.5236)によって計算することにより、Rockwell らによる、J Natl. Cancer Inst. 1972; 49:735-747に記載されたようにして腫瘍の大きさを1週間に二回測定した。
本明細書に開示された全ての特徴は、任意の組み合わせで組み合わせられうる。本明細書に開示されたそれぞれの特徴は、同一の、均等な、または類似の目的を達成する他の特徴により置換されうる。よって、特記しない限り、開示されたそれぞれの特徴は、広範な一連の均等な、または類似の特徴の一例に過ぎない。
Claims (16)
- 下記式の化合物:
XおよびYは、それぞれ独立して、H、アルキル、若しくはハロゲンであるか、または、XおよびYは一緒になって、−CH2−、−(CH2)2−、−(CH2)CRaRb(CH2)−、−(CH2)NRa(CH2)−、若しくは−(CH2)O(CH2)−であり、RaおよびRbは、それぞれ独立して、H、アルキル、−C(O)−アルキル、−C(O)−シクロアルキル、−C(O)−NH−アルキル、若しくは−C(O)−NH−シクロアルキルであり;かつ、
R1、R2、R3、R4、R5、R1’、R2’、R3’、R4’、およびR5’は、それぞれ独立して、H、アルキル、ハロゲン、OH、Rc−O−、RdS(O)2−O−、(Rd)2P(O)−O−、または(RdO)2P(O)−O−であり、Rcは無置換のアルキル、若しくは、ハロゲン、OH、アルコキシ、アミノ、シクロアルキル、ヘテロシクロアルキル、アリール、若しくはヘテロアリールで置換されたアルキルであり、かつ、Rdは、H、OH、C 2 −C 10 アルキル、アルコキシ、またはアリールであり;ここで、R1、R2、R3、R4、R5、R1’、R2’、R3’、R4’、およびR5’の少なくとも一つは、RdS(O)2−O−、(Rd)2P(O)−O−、または(RdO)2P(O)−O−である。 - XおよびYはそれぞれHである、請求項1に記載の化合物。
- R2はRdS(O)2−O−、(Rd)2P(O)−O−または(RdO)2P(O)−O−である、請求項1または2に記載の化合物。
- R2’はR−O−であり、Rはアミノで置換されたアルキルである、請求項1〜3のいずれか1項に記載の化合物。
- R2’はRdS(O)2−O−、(Rd)2P(O)−O−、または(RdO)2P(O)−O−である、請求項1〜3のいずれか1項に記載の化合物。
- R1’、R3’、およびR4’のうち、何れか一つはRdS(O)2−O−、(Rd)2P(O)−O−、または(RdO)2P(O)−O−である、請求項1〜5のいずれか1項に記載の化合物。
- R2はC2H5S(O)2−O−、(C2H5)2P(O)−O−、または(C2H5O)2P(O)−O−である、請求項1〜6のいずれか1項に記載の化合物。
- 化合物5〜7、9〜11、14、18、22、23、26〜29、34、37、40、43、48〜50、65、66、69、70、74、76、77、および79からなる群から選択される、請求項1に記載の化合物。
- 下記式の化合物:
XはNまたはCHであり;
R1、R2、R3、R4、R5、R1’、R2’、R3’、R4’、およびR5’は、それぞれ独立して、H、アルキル、ハロゲン、OH、Rc−O−、RdS(O)2−O−、(Rd)2P(O)−O−、または(RdO)2P(O)−O−であり、Rcは無置換のアルキル、若しくはハロゲン、OH、アルコキシ、アミノ、シクロアルキル、ヘテロシクロアルキル、アリール、若しくはヘテロアリールで置換されたアルキルであり、かつ、Rdは、H、アルキル、またはアリールであり;かつ、
R6はC(O)−Re またはC(O)NRe R f であり;Re は、シクロプロピルであり、Rf は、アルキルまたはシクロアルキルである。 - XはNである、請求項9に記載の化合物。
- R6はシクロプロピルカルボニルである、請求項9または10に記載の化合物。
- R2はR−O−であり、Rは、アミノで置換されたアルキルである、請求項9〜11のいずれか1項に記載の化合物。
- R2はOHである、請求項9〜11のいずれか1項に記載の化合物。
- 化合物16、45、および46からなる群から選択される、請求項9に記載の化合物。
- 請求項1〜14のいずれか1項に記載の化合物を含む、癌の治療のための薬剤。
- 前記癌は、大腸癌、前立腺癌、肺癌、腎臓癌、膀胱癌、乳癌、肝臓癌、膵臓癌、胃癌、子宮頚癌、卵巣癌、神経膠腫、メラノーマ、リンパ腫、多発性骨髄腫、白血病である、請求項15に記載の薬剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37553410P | 2010-08-20 | 2010-08-20 | |
US61/375,534 | 2010-08-20 | ||
PCT/US2011/047899 WO2012024282A2 (en) | 2010-08-20 | 2011-08-16 | 1,5-diphenyl-penta-1,4-dien-3-one compounds |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013536227A JP2013536227A (ja) | 2013-09-19 |
JP2013536227A5 JP2013536227A5 (ja) | 2014-09-25 |
JP5998139B2 true JP5998139B2 (ja) | 2016-09-28 |
Family
ID=45594547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013525975A Expired - Fee Related JP5998139B2 (ja) | 2010-08-20 | 2011-08-16 | 1,5−ジフェニル−ペンタ−1,4−ジエン−3−オン化合物 |
Country Status (12)
Country | Link |
---|---|
US (2) | US8822732B2 (ja) |
EP (3) | EP2606021B1 (ja) |
JP (1) | JP5998139B2 (ja) |
KR (1) | KR101907631B1 (ja) |
CN (3) | CN103459361A (ja) |
AR (2) | AR082856A1 (ja) |
AU (1) | AU2011292144B2 (ja) |
CA (1) | CA2807776C (ja) |
NZ (1) | NZ607653A (ja) |
SG (1) | SG188217A1 (ja) |
TW (1) | TWI574686B (ja) |
WO (1) | WO2012024282A2 (ja) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101907631B1 (ko) * | 2010-08-20 | 2018-10-12 | 알리안츠 파마사이언스 리미티드 | 1,5-디페닐-펜타-1,4-디엔-3-온 화합물 |
US9884825B2 (en) | 2012-08-03 | 2018-02-06 | Georgia State University Research Foundation, Inc. | Curcumin analogs and methods of making and using thereof |
CN103910616A (zh) * | 2014-03-20 | 2014-07-09 | 浙江工业大学 | 一种姜黄素衍生物及其制备与应用 |
CN104974038B (zh) * | 2014-04-13 | 2019-04-30 | 江苏康缘药业股份有限公司 | 一种含羧基单羰基姜黄素衍生物及其制备方法和应用 |
CN103922911A (zh) * | 2014-04-17 | 2014-07-16 | 上海应用技术学院 | 一种(1e,4e)-1,5-二(邻溴间甲氧基苯基)-1,4-戊二烯酮化合物及合成方法 |
WO2019152536A1 (en) * | 2018-01-30 | 2019-08-08 | The Regents Of The University Of California | Inhibitors of the wnt/beta-catenin pathway |
JP2021517167A (ja) * | 2018-03-08 | 2021-07-15 | ピーアイ セラピューティクス リミテッド | タンパク質分解を阻害するための化合物および癌の治療におけるその使用方法 |
CN108864188B (zh) * | 2018-09-06 | 2020-06-23 | 贵州大学 | 一种含亚磷酸酯的1,4-戊二烯-3-酮类衍生物、其制备方法及应用 |
CN109970704B (zh) * | 2019-04-22 | 2022-01-28 | 贵州大学 | 一种含噻吩磺酸酯的查耳酮类衍生物、其制备方法及应用 |
CN109942540B (zh) * | 2019-04-22 | 2021-06-18 | 贵州大学 | 一种含噻吩磺酸酯的1,4-戊二烯-3-酮类衍生物、其制备方法及应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2084208A1 (en) * | 1990-05-17 | 1991-11-18 | Barry Markaverich | Growth inhibitors and methods of treating cancer and cell proliferative diseases |
JPH0829977A (ja) * | 1994-07-18 | 1996-02-02 | Nippon Zeon Co Ltd | ポジ型レジスト組成物 |
JP3383724B2 (ja) * | 1995-05-11 | 2003-03-04 | ライオン株式会社 | 分散剤 |
CA2393440A1 (en) | 1999-12-03 | 2001-06-07 | Emory University | Curcumin analogs with anti-tumor and anti-angiogenic properties |
US20050069551A1 (en) * | 2002-03-08 | 2005-03-31 | Emory University | Cytotoxic compound-protein conjugates as suppressors of tumor growth and angiogenesis |
US20060276536A1 (en) | 2004-02-12 | 2006-12-07 | Vander Jagt David L | Cancer treatment using curcumin derivatives |
US8178727B2 (en) * | 2005-06-27 | 2012-05-15 | National University Corporation Tohoku University | Bis(arylmethylidene)acetone compound, anti-cancer agent, carcinogenesis-preventive agent, inhibitor of expression of Ki-Ras, ErbB2, c-Myc and Cycline D1, β-catenin-degrading agent, and p53 expression enhancer |
JP2008029977A (ja) * | 2006-07-31 | 2008-02-14 | Ntn Corp | エアロゾル吐出ノズルおよび被膜形成装置 |
EP2993165B1 (en) * | 2007-01-08 | 2018-06-27 | Allianz Pharmascience Ltd | Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof |
WO2010045395A2 (en) * | 2008-10-14 | 2010-04-22 | Danyang Chen | Curcumin analog compositions and related methods |
CN101475455A (zh) * | 2009-02-10 | 2009-07-08 | 贵州大学 | 1,5-二取代芳基-1,4-戊二烯-3-酮衍生物及制备方法和用途 |
KR101907631B1 (ko) * | 2010-08-20 | 2018-10-12 | 알리안츠 파마사이언스 리미티드 | 1,5-디페닐-펜타-1,4-디엔-3-온 화합물 |
-
2011
- 2011-08-16 KR KR1020137004265A patent/KR101907631B1/ko active IP Right Grant
- 2011-08-16 CN CN2011800404067A patent/CN103459361A/zh active Pending
- 2011-08-16 CA CA2807776A patent/CA2807776C/en not_active Expired - Fee Related
- 2011-08-16 JP JP2013525975A patent/JP5998139B2/ja not_active Expired - Fee Related
- 2011-08-16 AU AU2011292144A patent/AU2011292144B2/en not_active Ceased
- 2011-08-16 WO PCT/US2011/047899 patent/WO2012024282A2/en active Application Filing
- 2011-08-16 SG SG2013011127A patent/SG188217A1/en unknown
- 2011-08-16 NZ NZ607653A patent/NZ607653A/en not_active IP Right Cessation
- 2011-08-16 CN CN201710311577.8A patent/CN107253915A/zh active Pending
- 2011-08-16 CN CN201710311576.3A patent/CN107266340A/zh active Pending
- 2011-08-16 US US13/210,728 patent/US8822732B2/en not_active Expired - Fee Related
- 2011-08-16 EP EP11818654.3A patent/EP2606021B1/en not_active Not-in-force
- 2011-08-16 EP EP19177745.7A patent/EP3564204A1/en not_active Withdrawn
- 2011-08-16 EP EP16152929.2A patent/EP3045445B1/en not_active Not-in-force
- 2011-08-18 AR ARP110103015A patent/AR082856A1/es not_active Application Discontinuation
- 2011-08-19 TW TW100129846A patent/TWI574686B/zh not_active IP Right Cessation
-
2014
- 2014-08-28 US US14/471,539 patent/US9359279B2/en active Active
-
2018
- 2018-09-04 AR ARP180102505A patent/AR112787A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20140107097A (ko) | 2014-09-04 |
TW201212905A (en) | 2012-04-01 |
WO2012024282A3 (en) | 2012-04-26 |
US20140371177A1 (en) | 2014-12-18 |
EP3045445A1 (en) | 2016-07-20 |
EP2606021B1 (en) | 2019-07-31 |
AU2011292144B2 (en) | 2016-07-14 |
KR101907631B1 (ko) | 2018-10-12 |
AR082856A1 (es) | 2013-01-16 |
US20120046247A1 (en) | 2012-02-23 |
AU2011292144A1 (en) | 2013-03-14 |
US8822732B2 (en) | 2014-09-02 |
CN107253915A (zh) | 2017-10-17 |
SG188217A1 (en) | 2013-04-30 |
EP2606021A2 (en) | 2013-06-26 |
TWI574686B (zh) | 2017-03-21 |
JP2013536227A (ja) | 2013-09-19 |
EP3045445B1 (en) | 2019-08-07 |
CN107266340A (zh) | 2017-10-20 |
AR112787A2 (es) | 2019-12-11 |
CA2807776C (en) | 2018-10-09 |
CA2807776A1 (en) | 2012-02-23 |
US9359279B2 (en) | 2016-06-07 |
NZ607653A (en) | 2014-09-26 |
EP3564204A1 (en) | 2019-11-06 |
CN103459361A (zh) | 2013-12-18 |
EP2606021A4 (en) | 2014-05-07 |
WO2012024282A2 (en) | 2012-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5998139B2 (ja) | 1,5−ジフェニル−ペンタ−1,4−ジエン−3−オン化合物 | |
AU2020275818B2 (en) | Fluorine-containing compound and anti-cancer medical use thereof | |
KR101990605B1 (ko) | 아미노피리미딘 키나아제 억제제 | |
KR100737090B1 (ko) | 축합 이미다졸륨 유도체 | |
TW201910329A (zh) | 取代五元并六元雜環類化合物、其製備方法、藥物組合及其用途 | |
CN112851663B (zh) | 一种并杂环化合物及其用途 | |
JP2019512459A (ja) | 7員環化合物、その調製方法、その医薬組成物、およびその使用 | |
DK1643987T3 (en) | podophyllotoxin | |
KR20180096575A (ko) | Egfr 키나아제 억제제 및 이의 제조 방법과 응용 | |
JP2023502458A (ja) | ピラゾロヘテロアリール系誘導体、その調製方法及びその医薬的応用 | |
CN102724975A (zh) | IRE-1α抑制剂 | |
JP7245918B2 (ja) | サルササポゲニン構造に基づく誘導体、医薬組成物及びその使用 | |
CN110105356B (zh) | 一种氮杂吲哚类化合物及其制备方法和用途 | |
BR112020015747A2 (pt) | Conjugados de fármaco de moléculas pequenas de derivados de gemcitabina | |
JP2023538638A (ja) | ピラゾールボロン酸化合物、それを含有する医薬組成物、及びそれらの使用 | |
JP2022542449A (ja) | Stat3二機能性リン酸化部位を標的とするトリアロマティック化合物のクラスおよびその応用 | |
KR102450287B1 (ko) | 바이러스 감염 및 추가적인 질환의 치료를 위한 피리미딘 프로드러그 | |
JPH05503705A (ja) | 5―酸素化―2,4,6―トリアミノピリミジン類 | |
JP2017503026A (ja) | 水溶性4−アザポドフィルロトキシン類似体 | |
Crooks et al. | Use of parthenolide derivatives as antileukemic and cytotoxic agents | |
CN115916775A (zh) | Atr抑制剂及其用途 | |
CN114105977A (zh) | ***受体调节剂化合物及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20130807 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130808 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140806 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140806 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150416 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150428 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150728 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160202 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160427 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20160526 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20160526 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160809 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160829 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5998139 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |